Thermo Fisher Scientific Wins Three R&D 100 Awards Category: Corporate
Thermo Fisher Scientific Inc. has announced that three of its analytical instruments were included on the R&D Magazine list of the year’s top 100 technology innovations. Known as the “Oscars of Innovation,” the R&D 100 recognises the best new products across industry, academia and government-sponsored research.
“Innovation is a key component of our growth strategy and critical to fulfilling our mission, which is to enable our customers to make the world healthier, cleaner and safer,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “The R&D 100 awards recognise our commitment to technology development and our focus on giving customers the tools they need to achieve their own goals for innovation and productivity.”
The award-winning products are
• Thermo Scientific Delta Ray, an isotope ratio infrared spectrometer that enables scientists to monitor volcanos, greenhouse gases, plant ecology, and carbon capture and storage, among other applications for CO2 analysis. The Delta Ray spectrometer gives scientists real-time results at the sample source, eliminating bottlenecks created when transporting samples from the field to the lab.
• Thermo Scientific RIIDEye X, a handheld radiation isotope identifier designed to detect gamma and neutron radiation sources and provide information on location, type and quantity. The RIIDEye X delivers fast, accurate readings in harsh operating conditions, making it ideal for military personnel, first responders and field-based researchers.
• Thermo Scientific Dionex ERS 500, the first electrolytically regenerated, high-capacity membrane suppressor that eliminates the need for chemical reagents during ion chromatography analysis. Designed for use in environmental, food and beverage, and pharmaceutical markets, the ERS 500 suppressor is more pressure tolerant than previous technologies, a feature critical to long-term reliability.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.